The use of cannabis as a therapeutic agent for various health-related conditions has been nicely documented. Nonetheless, clinical trials in sufferers with Parkinson illness (PD) have yielded conflicting benefits. The aim of the present open-label observational study was to assess the clinical impact of cannabis on motor and non-motor symptoms of PD.
Twenty-two sufferers with PD attending the motor disorder clinic of a tertiary health-related center in 2011 to 2012 had been evaluated at baseline and 30 minutes right after smoking cannabis using the following battery: Unified Parkinson Illness Rating Scale, visual analog scale, present discomfort intensity scale, Brief-Type McGill Discomfort Questionnaire, as nicely as Healthcare Cannabis Survey National Drug and Alcohol Investigation Center Questionnaire.
Imply (SD) total score on the motor Unified Parkinson Illness Rating Scale score enhanced substantially from 33.1 (13.eight) at baseline to 23.two (10.five) after cannabis consumption (t = five.9 P < .001). Evaluation of certain motor symptoms revealed substantial improvement after remedy in tremor (P < .001), rigidity (P = .004), and bradykinesia (P < .001).
There was also substantial improvement of sleep and discomfort scores. No substantial adverse effects of the drug had been observed. The study suggests that cannabis might have a spot in the therapeutic armamentarium of PD. Bigger, controlled research are necessary to confirm the benefits.